SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lindberg M)
 

Sökning: WFRF:(Lindberg M) > Acquired Immune Res...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003787naa a2200637 4500
001oai:gup.ub.gu.se/258836
003SwePub
008240528s2017 | |||||||||||000 ||eng|
024a https://gup.ub.gu.se/publication/2588362 URI
024a https://doi.org/10.1158/0008-5472.can-16-31722 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Donia, M.4 aut
2451 0a Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN gamma Signaling
264 c 2017-08-31
264 1b American Association for Cancer Research (AACR),c 2017
520 a Cancer immunotherapy can result in durable tumor regressions in some patients. However, patients who initially respond often experience tumor progression. Here, we report mechanistic evidence of tumoral immune escape in an exemplary clinical case: a patient with metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic complete regression after T-cell-based immunotherapy. Functional cytotoxic T-cell responses, including responses to one mutant neoantigen, were amplified effectively with therapy and generated durable immunologic memory. However, these immune responses, including apparently effective surveillance of the tumor mutanome, did not prevent recurrence. Alterations of the MHC class I antigen-processing and presentation machinery (APM) in resistant cancer cells, but not antigen loss or impaired IFN gamma signaling, led to impaired recognition by tumor-specific CD8(+) T cells. Our results suggest that future immunotherapy combinations should take into account targeting cancer cells with intact and impaired MHC class I-related APM. Loss of target antigens or impaired IFN gamma signaling does not appear to be mandatory for tumor relapse after a complete radiologic regression. Personalized studies to uncover mechanisms leading to disease recurrence within each individual patient are warranted.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a cancer-immunotherapy
653 a metastatic melanoma
653 a cell therapy
653 a t-cells
653 a reactivity
653 a responses
653 a Oncology
700a Harbst, K.4 aut
700a van Buuren, M.4 aut
700a Kvistborg, P.4 aut
700a Lindberg, Mattias Fu Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center4 aut
700a Andersen, R.4 aut
700a Idorn, M.4 aut
700a Ahmad, S. M.4 aut
700a Ellebaek, E.4 aut
700a Mueller, A.4 aut
700a Fagone, P.4 aut
700a Nicoletti, F.4 aut
700a Libra, M.4 aut
700a Lauss, M.4 aut
700a Hadrup, S. R.4 aut
700a Schmidt, H.4 aut
700a Andersen, M. H.4 aut
700a Straten, P. T.4 aut
700a Nilsson, J. A.4 aut
700a Schumacher, Tonu Gothenburg University,Göteborgs universitet,Sahlgrenska Cancer Center4 aut
700a Seliger, B.4 aut
700a Jonsson, G.4 aut
700a Svane, I. M.4 aut
710a Göteborgs universitetb Sahlgrenska Cancer Center4 org
773t Cancer Researchd : American Association for Cancer Research (AACR)g 77:17, s. 4562-4566q 77:17<4562-4566x 0008-5472x 1538-7445
856u https://cancerres.aacrjournals.org/content/canres/77/17/4562.full.pdf
8564 8u https://gup.ub.gu.se/publication/258836
8564 8u https://doi.org/10.1158/0008-5472.can-16-3172

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy